The Rezvani group demonstrated that expression of IL-15 combined with an anti-CD19 CAR improved CB-derived NK cell cytotoxicity towards CD19-expressing cell lines and primary leukemia cells in vitro, and markedly extended survival in a Raji lymphoma xenograft model (86). This evidence concerns the gene CD19 and leukemia.